{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:06:13Z","timestamp":1758845173421,"version":"3.44.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary fibrosis is a severe and potentially fatal adverse event, and its association with disease-modifying antirheumatic drugs (DMARDs) has raised long-standing concerns. However, systematic investigations on this topic are lacking. This study aims to analyze the drug-specific safety signals, characteristics, and potential patient risk factors of DMARDs-related pulmonary fibrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted reports of pulmonary fibrosis events related to 36 types of DMARDs from the U.S. FDA\u2019s adverse event reporting system (FAERS) and WHO-VigiAccess databases. Full database-wide and active-comparator restricted disproportionality analyses were conducted to identify the strength of safety signals for different DMARDs. Multivariable logistic regression was used to analyze risk factors for pulmonary fibrosis events associated with DMARDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In FAERS, 4,869 cases of pulmonary fibrosis were reported among 2,456,021 adverse event reports involving DMARDs. Similarly, VigiAccess documented 4,847 pulmonary fibrosis cases out of 3,488,917 DMARD adverse events. Methotrexate (reporting odds ratio in VigiAccess [ROR <jats:sub>VigiAccess<\/jats:sub>] = 4.39, 95% CI: 4.11\u20134.70), leflunomide (ROR <jats:sub>VigiAccess<\/jats:sub> = 3.26, 95% CI: 2.75\u20133.86), sulfasalazine (ROR <jats:sub>VigiAccess<\/jats:sub> = 2.33, 95% CI: 1.91\u20132.84), rituximab (ROR <jats:sub>VigiAccess<\/jats:sub> = 1.43, 95% CI: 1.27\u20131.61), and tocilizumab (ROR <jats:sub>VigiAccess<\/jats:sub> = 1.28, 95% CI: 1.08\u20131.51) consistently showed significant disproportionality signals across both databases, suggesting a potential safety concern for pulmonary fibrosis. Multivariable analysis identified older age (&amp;gt;65\u00a0years) as a strong and consistent risk factor across all DMARD classes, while the influence of sex varied by drug. The time to onset of pulmonary fibrosis differed significantly across different DMARDs, with B-cell inhibitors showing the shortest onset (median: 113\u00a0days, IQR = 54\u2013397) and TNF-\u03b1 inhibitors the longest (median: 523\u00a0days, IQR = 143\u20131,185).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study revealed varying degrees of pulmonary fibrosis signals related to DMARDs, with significantly overreporting observed in certain conventional and biologic DMARDs. Age was identified as a key susceptibility factor. As the use of these agents expands, clinicians should remain vigilant in monitoring for pulmonary fibrosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1604895","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:30:03Z","timestamp":1758778203000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"111456","DOI":"10.1016\/j.intimp.2023.111456","article-title":"Regulation of miRNA-155-5p ameliorates NETosis in pulmonary fibrosis rat model via inhibiting its target cytokines IL-1\u03b2, TNF-\u03b1 and TGF-\u03b21","volume":"127","author":"Adel","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1165\/rcmb.2020-0387OC","article-title":"Antifibrotics modify B-cell-induced fibroblast migration and activation in patients with idiopathic pulmonary fibrosis","volume":"64","author":"Ali","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/ard.2005.044453","article-title":"Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab","volume":"65","author":"Allanore","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.100641","article-title":"Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab","volume":"38","author":"Cohen","year":"2011","journal-title":"J. Rheumatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.therap.2018.09.076","article-title":"The value of a health insurance database to conduct pharmacoepidemiological studies in oncology","volume":"74","author":"Conte","year":"2019","journal-title":"Therapie"},{"key":"B7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S2215-0366(19)30298-6","article-title":"Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health","volume":"7","author":"Davis","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00296-020-04773-4","article-title":"Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review","volume":"41","author":"Dawson","year":"2021","journal-title":"Rheumatol. Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","article-title":"Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008-19: cross sectional study","volume":"379","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/jama.2023.26504","article-title":"Disease-modifying drugs for adult-onset rheumatoid arthritis","volume":"331","author":"Faison","year":"2024","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","article-title":"Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatol. (United Kingdom)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"154680","DOI":"10.1016\/j.phymed.2023.154680","article-title":"Hesperidin inhibits lung fibroblast senescence via IL-6\/STAT3 signaling pathway to suppress pulmonary fibrosis","volume":"112","author":"Han","year":"2023","journal-title":"Phytomedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/rheumatology\/kel220","article-title":"Adalimumab-associated pulmonary fibrosis","volume":"45","author":"Huggett","year":"2006","journal-title":"Rheumatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2169\/internalmedicine.43.1201","article-title":"Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction","volume":"43","author":"Kamata","year":"2004","journal-title":"Intern. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s00296-002-0227-6","article-title":"Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - a prospective study","volume":"22","author":"Khadadah","year":"2002","journal-title":"Rheumatol. Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.joim.2023.11.003","article-title":"Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: an exploratory randomized controlled trial","volume":"21","author":"Li","year":"2023","journal-title":"J. Integr. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4939-7113-8_2","article-title":"The bleomycin model of pulmonary fibrosis","volume":"1627","author":"Liu","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.jiph.2022.08.007","article-title":"Association of TNF-\u03b1, TGF-\u03b21, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19","volume":"15","author":"Maranatha","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"13832","DOI":"10.3390\/ijms241813832","article-title":"Blood immunophenotypes of idiopathic pulmonary fibrosis: relationship with disease severity and progression","volume":"24","author":"Mendoza","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10165-006-0506-2","article-title":"Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage","volume":"16","author":"Ochi","year":"2006","journal-title":"Mod. Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1136\/bmj.329.7477.1266","article-title":"Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab","volume":"329","author":"Ostor","year":"2004","journal-title":"Br. Med. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2200957","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2101469","DOI":"10.1183\/13993003.01469-2021","article-title":"Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis","volume":"60","author":"Pr\u00eale","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s11010-023-04845-6","article-title":"Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventions","volume":"479","author":"Saha","year":"2024","journal-title":"Mol. Cell Biochem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1445-5994.2006.01035.x","article-title":"Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports","volume":"36","author":"Savage","year":"2006","journal-title":"Intern Med. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/art.21716","article-title":"Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab","volume":"55","author":"Schoe","year":"2006","journal-title":"Arthritis Care Res. Hob."},{"key":"B36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14740338.2024.2348575","article-title":"A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis","volume":"23","author":"Sen","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.4103\/0253-7613.190766","article-title":"VigiAccess: promoting public access to VigiBase","volume":"48","author":"Shankar","year":"2016","journal-title":"Indian J. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jbspin.2007.04.028","article-title":"Exacerbation of interstitial lung disease during etanercept therapy: two cases","volume":"75","author":"Tournadre","year":"2008","journal-title":"Jt. Bone Spine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v077.i01","article-title":"Ranger: a fast implementation of random forests for high dimensional data in C++ and R","volume":"77","author":"Wright","year":"2017","journal-title":"J. Stat. Softw."},{"key":"B43","doi-asserted-by":"publisher","first-page":"113074","DOI":"10.1016\/j.biopha.2022.113074","article-title":"Application and pharmacological mechanism of methotrexate in rheumatoid arthritis","volume":"150","author":"Zhao","year":"2022","journal-title":"Biomed. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1604895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:30:04Z","timestamp":1758778204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1604895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":43,"alternative-id":["10.3389\/fphar.2025.1604895"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1604895","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1604895"}}